A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently

Updated 06/21/2024

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety of VAC85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (MPNs).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05444530
Study type	Interventional
Source	Janssen Research & Development, LLC
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	July 21, 2022
Completion date	November 27, 2027

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT04866056` - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.	Phase 1/Phase 2
	Recruiting	`NCT05936359` - A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Phase 1
	Completed	`NCT02084563` - Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms	Phase 2
	Recruiting	`NCT04339400` - A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms	Phase 1
	Completed	`NCT02125318` - A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders	Phase 2
	Not yet recruiting	`NCT06291987` - Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation	Phase 1
	Recruiting	`NCT03314974` - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	Phase 2
	Completed	`NCT03075826` - A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms	Phase 2
	Recruiting	`NCT02823210` - Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
	Not yet recruiting	`NCT06313593` - A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms	Phase 1
	Active, not recruiting	`NCT03912064` - A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT	Phase 1
	Terminated	`NCT02393248` - Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)	Phase 1/Phase 2
	Completed	`NCT02076191` - Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	Phase 1/Phase 2
	Active, not recruiting	`NCT04761770` - Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders	Phase 2
	Recruiting	`NCT06034002` - A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms	Phase 1
	Completed	`NCT00949364` - Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage	Phase 2
	Completed	`NCT00053196` - Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer	Phase 2
	Terminated	`NCT01668173` - HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET	Phase 2
	Active, not recruiting	`NCT03618485` - Registry of Patients With MPNs in Taiwan